EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab

Zunahme RSV-assoziierter Hospitalisierungen und ambulanter Besuche bei sehr frühgeborenen Kindern im ersten Lebensjahr nach Wegfall des Zugangs zu Palivizumab

Yolanda Evong, Jiaxin Luo, Lingyun Ye, John Fahey, Janis L Breeze, Rebecca Attenborough, Kenny Wong, Joanne M Langley iD

American Journal of Perinatology · 2026-01 · 43 (01) · 118-121

DOI: 10.1055/a-2512-9453 ↗

Auf einen Blick

Bei sehr frühgeborenen Kindern in Nova Scotia war der Wegfall des Zugangs zu Palivizumab mit mehr RSV-assoziierten Hospitalisierungen und ambulanten Besuchen im ersten Lebensjahr verbunden.

Fragestellung

Ob der Entzug des Zugangs zu Palivizumab bei zuvor berechtigten Frühgeborenen mit Änderungen bei RSV-assoziierten Hospitalisierungen, Todesfällen oder ambulanten Besuchen verbunden ist.

Methode

Retrospektive Kohortenstudie in Nova Scotia; Verknüpfung von 6 bevölkerungsbasierten Provinzdatenbanken; Geburten zwischen April 2012 und September 2019; Nachverfolgung im ersten Lebensjahr.

Ergebnisse

Von 4.835 Geborenen waren 250 in die Kohorte eingeschlossen. RSV-H stieg nach eingeschränktem Zugang etwa 10-fach: von 0/123 auf 9,4 % (95 %-KI 5,0–15,9; Risikodifferenz 9,4). RSV-A stieg von 5,7 % auf 17,3 % (Risikodifferenz 11,6).

Schlussfolgerung der Autor:innen

Der Wegfall des Zugangs zu einer prophylaktischen Anti-RSV-monoklonalen Antikörperbehandlung war mit einem höheren Risiko für RSV-H und RSV-A verbunden.

Kernaussagen

  • RSV-H nahm nach Zugangsbeschränkung zu
  • RSV-A stieg von 5,7 % auf 17,3 %
  • Keine RSV-assoziierten Todesfälle beobachtet

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, online erschienen am 31.01.2025. Verfasst von Yolanda Evong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Dalhousie University Faculty of Medicine, Izaak Walton Killam Health Centre, Halifax, Nova Scotia, Canada. Hauptthemen laut MEDLINE: Palivizumab, Respiratory Syncytial Virus Infections, Hospitalization, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IWK Health Centre Mentored Research Award to Yolanda Evong.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

From 2002 to 2023, palivizumab was the only intervention to reduce respiratory syncytial virus (RSV)-associated hospitalizations in high-risk infants in Canada but advances in RSV prevention are drastically changing this landscape. Eligibility criteria for this monoclonal antibody for preterm infants varied over time across each of 10 Canadian provinces and 3 territories. The National Professional Pediatric Association (Canadian Pediatric Society) revised its eligibility recommendations in 2015, removing access for preterm infants 30 to 32 weeks gestation (WG). The province of Nova Scotia followed these recommendations the next season. This study aimed to determine if the removal of access to palivizumab in these previously eligible infants was associated with a change in hospital admissions, deaths, or ambulatory visits associated with RSV. We identified a retrospective cohort of Nova Scotia infants born between 30 and 32 WG, without other risk factors for RSV-H, from April 2012 to September 2019 by linking six population-based provincial databases, and followed each infant through the first year of life. Episodes of RSV-associated hospitalization (RSV-H), ambulatory visits (RSV-A), or death were identified by the International Statistical Classification of Diseases and Related Health Disorders (ICD) RSV-associated diagnostic codes. Of 4,835 infants born during the study period, 250 were 30 to 32 WG and eligible for the cohort. RSV-H increased approximately 10-fold following restricted access to palivizumab (from no RSV-H (0/123) to 9.4%; 95% CI 5.0, 15.9; risk difference 9.4), but no RSV-associated deaths occurred. RSV-A also increased from 5.7 to 17.3% (risk difference 11.6). Discontinuation of access to a prophylactic anti-RSV monoclonal antibody in very preterm infants was associated with a higher risk of RSV-H and RSV-A. Evaluation of health care policy change on patient well-being is essential to assess the impact and guide future decision-making at the population level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PalivizumabRespiratory Syncytial Virus InfectionsHospitalizationAntiviral AgentsAmbulatory CareInfant, Premature, DiseasesHumansRetrospective StudiesInfant, NewbornInfantFemaleMaleNova ScotiaInfant, PrematureInfant, Extremely PrematureGestational Age

Substanzen

PalivizumabAntiviral Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Dalhousie University Faculty of Medicine, Izaak Walton Killam Health Centre, Halifax, Nova Scotia, Canada.
  • Canadian Center for Vaccinology (Dalhousie University, IWK Health and Nova Scotia Health), Halifax, Nova Scotia, Halifax, Nova Scotia, Canada.
  • Canadian Centre for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Department of Reproductive Care of Nova Scotia, IWK Health Centre, Halifax, Nova Scotia, Canada.
  • Division of Pediatric Cardiology, Department of Pediatrics, Dalhousie University Faculty of Medicine, IWK Health Centre, Halifax, Nova Scotia, Canada.
  • Department of Pediatrics and Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.

ORCID-Profile: Joanne M Langley

Förderung

  • IWK Health Centre Mentored Research Award to Yolanda Evong

Zitieren

APA

Evong, Y., Luo, J., Ye, L., Fahey, J., Breeze, J. L., Attenborough, R., Wong, K., & Langley, J. M. (2026). Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab. American Journal of Perinatology, 43(01), 118-121. https://doi.org/10.1055/a-2512-9453

Vancouver

Evong Y, Luo J, Ye L, Fahey J, Breeze JL, Attenborough R, et al. Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab. American Journal of Perinatology. 2026;43(01):118-121. doi:10.1055/a-2512-9453

BibTeX
@article{Evong2026,
  author = {Evong, Yolanda and Luo, Jiaxin and Ye, Lingyun and Fahey, John and Breeze, Janis L and Attenborough, Rebecca and Wong, Kenny and Langley, Joanne M},
  title = {Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab},
  journal = {American Journal of Perinatology},
  year = {2026},
  volume = {43},
  number = {01},
  pages = {118--121},
  doi = {10.1055/a-2512-9453}
}
Kostenlos starten →